



Topical issues and forthcoming updates to TB screening recommendations and implementation guidance




Dr Cecily Miller
WHO Global Programme on
Tuberculosis & Lung Health,
Geneva, Switzerland



Global progress towards the Ending TB

We are **far off** our targets for the End TB Strategy and the 2023 UN High-Level Meeting


- Progress in reducing global incidence is stalled in much of the world
- Case detection is higher than ever but still short of our targets
- TPT coverage is improving but still very far from targets
- Almost one half of all people with TB face catastrophic costs



90% target for 2027

People living with HIV newly enrolled on ART

Households with TB



One challenge – Asymptomatic TB






Figure 3: Proportion of tuberculosis disease that is subclinical by two definitions, and by country
The left panel is aggregated over the full 12-country dataset. The right panel is disaggregated by country.

Stuck et al Lancet Infect Dis 2024

Another challenge – barriers to reaching care




Systematic screening for TB

Systematic TB Screening can improve global TB care by:

- **Protecting individuals at high risk**
 - Reduces delays in diagnosis
 - Improves treatment outcomes
 - Reduces costs for patients, families
- **Improving TB epidemiology of the community**
 - Increases detection of TB
 - Reduces transmission of TB
 - Reduces TB prevalence and incidence
- **Preventing TB entirely**
 - Enables initiation of TB preventive therapy




Overview of guidelines




Released **March 2021**, composed of 17 recommendations covering two major areas:

1. **Who to screen** – what populations and groups should be screened for TB disease
2. **How to screen** – what tools should be used for TB screening



<https://tbksp.who.int/en/node/127>



Recommendations: populations to be screened

TB screening is strongly recommended for:



**Household and
close contacts**



**People living
with HIV**




**Miners exposed
to silica dust**



Prisoners

These populations should always be screened in all global settings



Recommendations: populations to be screened

TB screening is strongly recommended for:



Child contacts of
people with TB



Children living with
HIV

- Very high risk of TB
- Higher risk of rapid progression from infection to disease

Recommendations: populations to be screened

TB screening is conditionally recommended for:

Facility-based screening/ intensified case finding (ICF):

People with risk factors for TB seeking health-care service in settings with $\geq 0.1\%$ TB prevalence

- ✓ Malnourishment
- ✓ Diabetes
- ✓ History of previous TB
- ✓ Chronic lung disease
- ✓ Health care workers
- ✓ Those with other risk factors for TB

People with untreated fibrotic lesions on chest X-ray

Community-based screening/ active case finding (ACF):

People with structural risk factors for TB and limited access to health care

- ✓ Urban poor
- ✓ Homeless
- ✓ Refugees
- ✓ Migrants
- ✓ Other vulnerable, marginalized groups

People in settings with 0.5% TB prevalence

Prioritization is needed depending on the setting, context.

Recommendations: tools for screening (>15 years)



- **Chest X-ray**
- **Computer-aided detection (CAD)**

- Highly sensitive for TB disease
- Can detect TB before onset of symptoms
- CAD approved in place of human reading of CXR for adults (>15 y)



Symptom screening:

- **Cough**
- **Multiple symptom**

- Feasible and easy to implement
- Low resource requirements
- Not highly accurate
- Does not detect everyone with TB



Rapid molecular tests

- Less sensitive as screening tool, less specific
- Still requires a follow-up test



Recommendations: tools for screening people with HIV

For adults & adolescents (>10 years) living with HIV:



Chest X-ray & CAD

- Improves the sensitivity of screening, particularly among those in regular ART care
- CAD only recommended for those 15 years & older



C-Reactive Protein

- A general marker of inflammation, can be used as a point-of-care test
- Increases specificity of screening, particularly among those not yet on ART



WHO 4-symptom screen (W4SS)

- Any one of cough, fever, night sweats, weight loss
- Recommended to be done at every health visit



Rapid molecular tests

- Can be used for screening all people living with HIV
- Strongly recommended for acutely ill and hospitalized patients in a “test and treat” strategy directly to treatment



Recommendations: tools for screening children



For child contacts of TB patients (≤ 15 years)




- Symptom screening (cough, fever, weight loss/lack of weight gain, reduced playfulness)
- Chest X-ray

For children living with HIV (≤ 10 years)




- Symptom screening (cough, fever, weight loss/lack of weight gain, reduced playfulness)
- Contact with TB patient



Screening guidelines– updates coming soon

- January 2025 – Technical Advisory Group meeting on CAD
 - Evaluation of CAD products as a stopgap measure while WHO PQ in development
 - Evaluated 8 currently available CAD products for diagnostic accuracy
 - Results available May 2025
- Updated Target Product Profiles for new TB screening tools
 - Expert consultation and public commentary held 2024
 - Update available 2025
- Future guideline updates for TB screening
 - Pediatric CAD software, other screening tools
 - Expanding the WHO evaluation of CAD beyond TB
 - Updates to screening tools and interventions to address asymptomatic TB



Operational handbook




The handbook provides


- Support on developing context-specific screening approaches
- A sound basis for national guidelines based on TB epidemiology in different risk groups and the health care system in the country

Target audience:

- Staff in national TB programmes and national HIV/AIDS programmes
- Other health programmes involved in screening in public and private sectors
- Communities and implementing partners





<https://tbksp.who.int/en/node>



Operational handbook

What are the principles of implementing high-quality, ethical screening practices?



Operational handbook

How to create, implement, and update a national TB screening strategy?

Assessing the situation



Setting goals and
specific objectives

Monitoring, evaluation,
and modifying the
programme

Identifying and
prioritizing risk groups


Planning, budgeting
and implementing

Choosing algorithms for
prioritized risk groups




Operational handbook - algorithms

Single screening test algorithm




Utilizes one screening test to distinguish between people who possibly have TB and are referred for TB diagnostic evaluation, and people who most likely don't have TB and can be assessed for TPT

Parallel screening algorithm




Utilizes two screening tests together – a positive result from either or both test is an indication for diagnostic evaluation




Operational handbook - algorithms

Positive sequential screening algorithm



Uses two screening tests - only those positive on the first test going on to a second screen, and only those positive on both screens go on for diagnosis



Negative sequential screening algorithm



Uses two screening tests - those positive on the first screen go straight to diagnostic evaluation, those negative on the first screen go on to a second screen – thus those positive on the second screen go on for diagnosis

Operational handbook


How to monitor and evaluate TB screening?



Implementation indicators	
Acceptability or Reach/coverage	B / A
Screening positivity rate	C / B
Screening retention in care	D / C
Testing positivity rate	E / D
Yield	E / A
Linkage to care	F / E
Treatment success	G / F
NNS	B / E

Population-level impact indicators

Incidence (~reduction in notified cases despite activities)
Prevalence (if being measured by intervention)
TB Mortality




Useful tools - *ScreenTB*

ScreenTB


- **Web-based tool to assist countries with prioritization of risk groups for screening and selection of screening tools and algorithms**
- **Harnesses data from a variety of sources – WHO Global TB Report, UN HIV data, published literature**
- **Produces estimates of yield and cost of screening, allowing for comparison between risk groups and across algorithm options within groups**
- **Creates figures to allow for easy visual analysis**

ScreenTB.org




Operational handbook – updates coming soon

- CAD – a pragmatic approach to threshold selection
 - Being developed with colleagues from MSF, based on implementation experience
 - A programmatic alternative to conducting a CAD calibration study
 - Feasible to implement rapidly, to enable CAD use when data or resources not available for full CAD calibration study
- Further implementation guidance for specific screening approaches
 - Facility-based screening
 - Community-based screening – a roadmap for scaling up TB screening
 - Risk group-specific screening (e.g. prisoners, miners, PLHIV, contacts)
 - “Best bet” algorithms for specific risk groups, settings



Acknowledgements

Dennis Falzon, Saskia den Boon, other WHO staff at HQ, Regional, Country Offices
Patients
Evidence Reviewers
National TB and HIV Programmes
Guideline Development Group, External Review Group
FIND, Stop TB Partnership, IoM
TAG, civil society
Global Fund, USAID
Other experts and funding agencies





© WORLD HEALTH ORGANIZATION 2025

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.